ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
- Jefferies London Healthcare Conference November 14, 2018 at 9:40 am ET/2:40 pm GMT
- Evercore ISI HealthConX November 27, 2018 at 8:45 am ET
- 30th Annual Piper Jaffray Healthcare Conference November 28, 2018 at 11:30 am ET
A webcast of each presentation will be accessible live through the Investors section of the Companys website, www.immunogen.com; a replay will be available in the same location for approximately two weeks.
ABOUT IMMUNOGEN ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to target a better now. Our lead product candidate, mirvetuximab soravtansine, is in a Phase 3 study for folate receptor alpha (FRÎ±)-positive platinum-resistant ovarian cancer, and in Phase 1b/2 testing in combination regimens. Our novel IGN candidates for hematologic malignancies, IMGN779 and IMGN632, are in Phase 1 studies.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
INVESTOR RELATIONS CONTACT
Chelcie Lister, 910-777-3049
Courtney O’Konek, 781-895-0600
Robert Stanislaro, 212-850-5657